US Patent No: 6,919,321

Number of patents in Portfolio can not be more than 2000

Ophthalmic lubricating solution adapted for use in lasik surgery

ALSO PUBLISHED AS: 20040009893

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Ocular lubricant solutions are described. The solutions are adapted to facilitate the formation of a corneal flap during LASIK surgery. The solutions contain one or more viscosity enhancing agents (e.g., chondroitin sulfate) in a substantially salt-free, ophthalmically acceptable vehicle. Methods of lubricating the cornea to facilitate flap formation are also described.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
ALCON, INC.HUNENBERG17

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Doshi, Uday Randolph, NJ 17 49
Jafari, Masoud R Arlington, TX 7 28
Maddox, Emerson Fort Worth, TX 2 13
Markwardt, Kerry L Mansfield, TX 17 73
Wang, Pao-Li Fort Worth, TX 6 15

Cited Art Landscape

Patent Info (Count) # Cites Year
 
Other [Check patent profile for assignment information] (2)
5,133,708 Method for controlled corneal ablation 45 1989
* 5,106,615 Eyedrops having non-Newtonian rheological properties 64 1990
 
MINNESOTA MINING AND MANUFACTURING COMPANY (1)
* 4,851,513 Viscoelastic collagen solution for opthalmic use and method of preparation 46 1987
 
Medjet, Inc. (1)
5,861,955 Topographical cornea mapping for corneal vision correction 44 1996
 
LABORATOIRE MEDIDOM S.A. (1)
5,770,628 Ophthalmic preparation for use as artificial tear 19 1995
 
ALCON MANUFACTURING, LTD. (1)
4,550,022 Tissue irrigating solution 73 1984
 
MDV TECHNOLOGIES, INC. (4)
5,277,911 Ablatable mask of polyoxyalkylene polymer and ionic polysaccharide gel for laser reprofiling of the cornea 43 1990
5,318,780 Medical uses of in situ formed gels 124 1991
5,587,175 Medical uses of in situ formed gels 84 1993
5,958,443 Medical uses of in situ formed gels 57 1996
 
ALCON RESEARCH, LTD. (2)
5,409,904 Hyaluronic acid compositions and methods 46 1992
5,578,578 Ophthalmic solutions 8 1995
 
ALLERGAN, INC. (1)
* 4,983,580 Methods and materials for use in corneal wound healing 63 1990
 
LABORATOIRES MERCK SHARP & DOHME-CHIBRET, A CORP. OF FRANCE (1)
4,861,760 Ophthalmological composition of the type which undergoes liquid-gel phase transition 126 1986
 
CHEMEDICA S.A. (1)
5,871,772 Sodium hyaluronate viscous solutions for use as masking fluid in therapeutic photokeratectomy by means of excimer laser 6 1995
 
UNIVERSITY OF SOUTHERN CALIFORNIA (1)
5,728,405 Method for preventing keratocyte loss 6 1996
 
Senju Pharmaceutical Co., Ltd. (1)
5,710,148 Corneal opacification inhibitory composition 3 1996
* Cited By Examiner

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
Other [Check patent profile for assignment information] (1)
7,820,639 Ophthalmic compositions including lubricant, deturgescent agent, and glycosaminoglycan and methods of using the same 1 2005
 
SYSMEX CORPORATION (1)
* 7,824,916 Sheath liquid for particle analyzer 0 2007
 
SIFI S.P.A. (2)
* 8,912,164 Re-epithelializing pharmaceutical compositions comprising xanthan gum 0 2003
* 2005/0234,011 Re-epithelializing pharmaceutical compositions comprising xanthan gum 3 2005
* Cited By Examiner

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jan 19, 2017
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00